A detailed history of Clearstead Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Clearstead Advisors, LLC holds 244 shares of CRSP stock, worth $10,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
244
Previous 863 71.73%
Holding current value
$10,716
Previous $40,000 77.5%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025

SELL
$38.65 - $55.15 $23,924 - $34,137
-619 Reduced 71.73%
244 $9,000
Q3 2024

Nov 13, 2024

BUY
$44.62 - $62.75 $1,874 - $2,635
42 Added 5.12%
863 $40,000
Q1 2024

May 14, 2024

BUY
$60.67 - $89.12 $48,657 - $71,474
802 Added 4221.05%
821 $55,000
Q4 2023

Feb 12, 2024

BUY
$38.62 - $72.18 $115 - $216
3 Added 18.75%
19 $1,000
Q3 2023

Nov 13, 2023

SELL
$45.39 - $59.0 $5,219 - $6,785
-115 Reduced 87.79%
16 $0
Q3 2023

Nov 07, 2023

BUY
$45.39 - $59.0 $5,219 - $6,785
115 Added 718.75%
131 $5,000
Q2 2023

Aug 07, 2023

BUY
$43.47 - $67.77 $695 - $1,084
16 New
16 $0
Q2 2022

Aug 12, 2022

BUY
$43.23 - $73.83 $432 - $738
10 Added 33.33%
40 $2,000
Q1 2022

May 04, 2022

SELL
$53.19 - $79.24 $14,042 - $20,919
-264 Reduced 89.8%
30 $2,000
Q4 2021

Feb 14, 2022

SELL
$70.09 - $111.29 $3,224 - $5,119
-46 Reduced 13.53%
294 $22,000
Q3 2021

Nov 12, 2021

BUY
$110.2 - $156.64 $32,398 - $46,052
294 Added 639.13%
340 $38,000
Q1 2021

May 14, 2021

SELL
$110.72 - $210.04 $664 - $1,260
-6 Reduced 11.54%
46 $6,000
Q4 2020

Feb 11, 2021

BUY
$79.67 - $173.23 $4,142 - $9,007
52 New
52 $8,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.43B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Clearstead Advisors, LLC Portfolio

Follow Clearstead Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.